Auswahl der wissenschaftlichen Literatur zum Thema „Disease progression score“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Disease progression score" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Disease progression score"
Shan, Guogen, Xinlin Lu, Zhigang Li, Jessica Z. K. Caldwell, Charles Bernick und Jeffrey Cummings. „ADSS: A Composite Score to Detect Disease Progression in Alzheimer’s Disease“. Journal of Alzheimer's Disease Reports 8, Nr. 1 (20.02.2024): 307–16. http://dx.doi.org/10.3233/adr-230043.
Der volle Inhalt der QuelleRoussanov, Bisser V., Jeremy M. G. Taylor und Janis V. Giorgi. „Calculation and use of an HIV-1 disease progression score“. AIDS 14, Nr. 17 (Dezember 2000): 2715–22. http://dx.doi.org/10.1097/00002030-200012010-00011.
Der volle Inhalt der QuellePihlstrøm, Lasse, Kristina Rebekka Morset, Espen Grimstad, Valeria Vitelli und Mathias Toft. „A cumulative genetic risk score predicts progression in Parkinson's disease“. Movement Disorders 31, Nr. 4 (08.02.2016): 487–90. http://dx.doi.org/10.1002/mds.26505.
Der volle Inhalt der QuelleUngaro, R., R. Jordan, C. Yzet, P. Bossuyt, F. Baert, T. Vanasek, G. R. D’Haens et al. „P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study“. Journal of Crohn's and Colitis 14, Supplement_1 (Januar 2020): S264—S266. http://dx.doi.org/10.1093/ecco-jcc/jjz203.369.
Der volle Inhalt der QuelleMoore, Ursula, Marni Jacobs, Meredith K. James, Anna G. Mayhew, Roberto Fernandez-Torron, Jia Feng, Avital Cnaan et al. „Assessment of disease progression in dysferlinopathy“. Neurology 92, Nr. 5 (09.01.2019): e461-e474. http://dx.doi.org/10.1212/wnl.0000000000006858.
Der volle Inhalt der QuelleShi, Manman, Yan Ouyang, Mingxin Yang, Meng Yang, Xiaoyan Zhang, Wei Huang, Weiming Wang et al. „IgA Nephropathy Susceptibility Loci and Disease Progression“. Clinical Journal of the American Society of Nephrology 13, Nr. 9 (24.07.2018): 1330–38. http://dx.doi.org/10.2215/cjn.13701217.
Der volle Inhalt der QuelleJönsson, Linus, Milana Ivkovic, Ron Handels, Anders Gustavsson, Teresa León, Julie Hviid Hahn-Pedersen und Lars Lau Raket. „OP142 Progression Analysis Versus Traditional Methods To Quantify Slowing Of Disease Progression In Alzheimer’s Disease“. International Journal of Technology Assessment in Health Care 39, S1 (Dezember 2023): S42. http://dx.doi.org/10.1017/s0266462323001435.
Der volle Inhalt der QuelleViticchi, Giovanna, Lorenzo Falsetti, Laura Buratti, Cristiano Boria, Simona Luzzi, Marco Bartolini, Leandro Provinciali und Mauro Silvestrini. „Framingham risk score can predict cognitive decline progression in Alzheimer's disease“. Neurobiology of Aging 36, Nr. 11 (November 2015): 2940–45. http://dx.doi.org/10.1016/j.neurobiolaging.2015.07.023.
Der volle Inhalt der QuelleRavindran, J., C. Cavill, C. Balakrishnan, S. M. Jones, E. Korendowych und N. J. McHugh. „A modified sharp score demonstrates disease progression in established psoriatic arthritis“. Arthritis Care & Research 62, Nr. 1 (15.01.2010): 86–91. http://dx.doi.org/10.1002/acr.20018.
Der volle Inhalt der QuelleKataoka, Hiroshi, und Kazuma Sugie. „Association between Fatigue and Hoehn-Yahr Staging in Parkinson’s Disease: Eight-Year Follow-Up Study“. Neurology International 13, Nr. 2 (26.05.2021): 224–31. http://dx.doi.org/10.3390/neurolint13020023.
Der volle Inhalt der QuelleDissertationen zum Thema "Disease progression score"
Albers, Timothy W. „Development of an Objective Motor Score for Monitoring the Progression and Severity of Parkinson's Disease“. PDXScholar, 2011. https://pdxscholar.library.pdx.edu/open_access_etds/104.
Der volle Inhalt der QuelleKmetzsch, Virgilio. „Multimodal analysis of neuroimaging and transcriptomic data in genetic frontotemporal dementia“. Electronic Thesis or Diss., Sorbonne université, 2022. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2022SORUS279.pdf.
Der volle Inhalt der QuelleFrontotemporal dementia (FTD) represents the second most common type of dementia in adults under the age of 65. Currently, there are no treatments that can cure this condition. In this context, it is essential that biomarkers capable of assessing disease progression are identified. This thesis has two objectives. First, to analyze the expression patterns of microRNAs taken from blood samples of patients, asymptomatic individuals who have certain genetic mutations causing FTD, and controls, to identify whether the expressions of some microRNAs correlate with mutation status and disease progression. Second, this work aims at proposing methods for integrating cross-sectional data from microRNAs and neuroimaging to estimate disease progression. We conducted three studies. Initially, we focused on plasma samples from C9orf72 expansion carriers. We identified four microRNAs whose expressions correlated with the clinical status of the participants. Next, we tested all microRNA signatures identified in the literature as potential biomarkers of FTD or amyotrophic lateral sclerosis (ALS), in two groups of individuals. Finally, in our third work, we proposed a new approach, using a supervised multimodal variational autoencoder, that estimates a disease progression score from cross-sectional microRNA expression and neuroimaging datasets with small sample sizes. The work conducted in this interdisciplinary thesis showed that it is possible to use non-invasive biomarkers, such as circulating microRNAs and magnetic resonance imaging, to assess the progression of rare neurodegenerative diseases such as FTD and ALS
CUCOVICI, ALIONA. „The Role of Nutrition and Other Lifestyle Habits in the Progression of Amyotrophic Lateral Sclerosis: A Multicentre Cross-Sectional Study“. Doctoral thesis, Università di Foggia, 2021. https://hdl.handle.net/11369/425207.
Der volle Inhalt der QuelleIntroduction: Amyotrophic Lateral Sclerosis (ALS) is a devastating and still untreatable motor neuron disease. The causes of ALS are unknown, but nutritional and lifestyle factors such as coffee and tea consumption, alcohol drinking, and cigarette smoking may impact the rate of disease progression. However, the currently used research methods and outcomes (punctual and not cumulative evaluation of quantity/frequency) do not adequately assess the effect of coffee and tea consumption, and alcohol intake, and cigarette smoking. This is one of the reasons why the nutritional lifestyle factors analysis for people with ALS in different studies sometimes has conflicting results. This study used a new approach to assess the role of potentially modifiable risk factors on the ALS progression. This study used cumulative lifetime coffee and tea consumption, alcohol drinking, and cigarette smoking loads. Lifetime coffee and tea consumption, alcohol drinking, and cigarette smoking loads are applied in the practice of oncologists, dieticians, and other areas of medicine, but not in neurological practice. These values allow us to estimate the cumulative effect of coffee and tea consumption, alcohol drinking, and cigarette smoking on disease course, even for low to moderate doses. A similar study was done for Multiple Sclerosis, another autoimmune and degenerative disease of the central nervous system. If some potentially modifiable lifestyle factors could impact on MS progression, possible interventions may be suggested, and possible clues to understand the pathogenesis of progression may be uncovered. Objectives: This PhD thesis aimed to evaluate the role of coffee and tea consumption, alcohol drinking, and cigarette smoking as potentially modifiable risk factors on ALS progression rate. Additional goals were to assess a possible role of lifetime coffee and tea consumption on Multiple Sclerosis progression and severity and their possible interaction with smoking and alcohol use; to investigate whether coffee and tea consumption interacts with HLA susceptibility risk genes in determining MS progression, as a comparative study. Subjects and Methods: In this multicentre cross-sectional study were recruited 241 patients, 96 females and 145 males; the mean age at onset was 59.9±11.8 years. According to El Escorial criteria, 74 were definite ALS, 77 probable, 55 possible, and 35 suspected; 187 patients had spinal onset and 54 bulbar. The patients were categorized into three groups, according to ΔFS (derived from ALS Functional Rating Scale-Revised score and disease duration from onset): slow (81), intermediate (80), and fast progressors (80). The design of the comparative study “The Impact of Lifetime Coffee and Tea Loads on Multiple Sclerosis Severity” was a cross-sectional study, 208 patients consecutively admitted to the Department of Neurology were asked to complete the “Questionnaire of Lifestyle” (part of the European Prospective Investigation into Cancer and Nutrition project). An estimation of the intensity of drinking (drinks/day) was calculated as the weighted sum of the mean number of standard cups drunk per day at different ages. A measure of lifetime load of the exposure was was expressed in terms of cups-year. Disease severity was estimated by the Multiple Sclerosis Severity Score (MSSS). Results: Current coffee consumers were 179 (74.3%), 34 (14.1%) were non-consumers, 22 (9.1%) former consumers, whereas six (2.5%) consumed decaffeinate coffee only. The log-ΔFS was weakly correlated with the duration of coffee consumption (p=0.034), but not with the number of cups-year (p=0.932). Current tea consumers were 101 (41.9%), 6 (2.5%) were former-consumers, and 134 (55.6%) non-consumers. Among 107 current and former consumers, 27 (25.2%) consumed only green tea, 51 (47.7%) other types of tea, and 29 (27.1%) both. The log-ΔFS was weakly correlated with the consumption duration of other tea types (p=0.028), but not with the number of cups-year. Current smokers were 44 (18.3%), 187 (77.6%) were non-smokers, and 10 (4.1%) former smokers. Age of ALS onset was lower in current smokers than non-smokers, and the ΔFS was slight, although not significantly, higher for smokers of >14 cigarettes/day. Current alcohol drinkers were 147 (61.0%), 5 patients (2.1%) were former-drinkers, and 89 (36.9%) non-drinkers. The log-ΔFS was weakly correlated with the duration of alcohol consumption (p=0.038), but not with the number of drinks-day or the drink-years. In the study “The Impact of Lifetime Coffee and Tea Loads on Multiple Sclerosis Severity” we did not find any trend with the quantity of coffee drunk for both the intensity and cumulative exposures. The multivariable analysis did not show any association between coffee and tea consumption (cups/day) and MSSS. Regarding tea consumption, we found no correlation with Multiple Sclerosis severity, measured with the MSSS, age at onset, or clinical form. Compared to non-consumers, the ORs were 1.27 for coffee drinkers, and 0.68 for tea drinkers. Conclusions: The study does not support the hypothesis that coffee or tea consumption is associated with ALS progression rate. The results of this cross-sectional multicenter study evidence a possible minor role for smoking, but not for alcohol drinking in worsening disease progression. The results of the comparative study “The Impact of Lifetime Coffee and Tea Loads on Multiple Sclerosis Severity” do not support the hypothesis that coffee or tea intake is associated with a different severity or progression of MS, contrarily to other neurodegenerative diseases. However, we cannot exclude a possible effect of higher doses of coffee or tea or an effect on a subgroup of patients.
Plan, Elodie L. „Pharmacometric Methods and Novel Models for Discrete Data“. Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-150929.
Der volle Inhalt der QuelleBuchteile zum Thema "Disease progression score"
Thushara, A., C. UshaDevi Amma, Ansamma John und Lida Mary Victor. „Modelling Cognitive Scores for Alzheimer’s Disease Progression Prediction Using Longitudinal MRI Data“. In 4th EAI International Conference on Big Data Innovation for Sustainable Cognitive Computing, 239–51. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-07654-1_17.
Der volle Inhalt der QuelleMohan, Sruthi, und d. S. Naganandhini. „Progression Prediction and Classification of Alzheimer’s Disease using MRI“. In Computational Intelligence and Machine Learning Approaches in Biomedical Engineering and Health Care Systems, 181–96. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9781681089553122010014.
Der volle Inhalt der QuelleGoetz, Ryan, Nitesh Kumar Jain, Humayun Anjum und Thomas S. Kaleekal. „Lung Transplantation in Idiopathic Pulmonary Fibrosis“. In Idiopathic Pulmonary Fibrosis [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.105725.
Der volle Inhalt der QuelleCalderón-Garcidueñas, Lilian, Partha S. Mukherjee, Randy J. Kulesza, Ricardo Torres-Jardón, Jacqueline Hernández-Luna, Rodrigo Ávila-Cervantes, Edgar Macías-Escobedo et al. „Mild Cognitive Impairment and Dementia Involving Multiple Cognitive Domains in Mexican Urbanites“. In Advances in Alzheimer’s Disease. IOS Press, 2021. http://dx.doi.org/10.3233/aiad210020.
Der volle Inhalt der QuelleCerda-Reyes, Eira, Alicia Sarahi Ojeda-Yuren, Julián Torres-Vazquez, María del Rosario Herrero Maceda, Martín Uriel Vázquez-Medina, Perla Denice Flores-Rangel, Yailin Fabiola Velásquez Palacios, Saraid Cerda-Reyes und Graciela Elia Castro-Narro. „Diagnosis of Nonalcoholic Steatohepatitis“. In Advances in Hepatology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96281.
Der volle Inhalt der QuelleMudigonda, Nihar. „Finding Relationship Between Alzheimer's Disease and Noise in Electroencephalogram (EEG) Data Using Novel Machine Learning (ML) Algorithms“. In Proceedings of the 2023 International IEMS Conference, March 5-7, 2023, 1–13. Wichita State University, 2023. http://dx.doi.org/10.62704/10057/26115.
Der volle Inhalt der QuelleZulian, Francesco. „Paediatric scleroderma and related disorders“. In Oxford Textbook of Rheumatology, 989–1000. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0122.
Der volle Inhalt der QuelleGoldman, Jean-Philippe, Luc Mottin, Jamil Zaghir, Daniel Keszthelyi, Belinda Lokaj, Hugues Turbé, Julien Gobeil, Patrick Ruch, Julien Ehrsam und Christian Lovis. „Classification of Oncology Treatment Responses from French Radiology Reports with Supervised Machine Learning“. In Studies in Health Technology and Informatics. IOS Press, 2022. http://dx.doi.org/10.3233/shti220605.
Der volle Inhalt der QuelleAnjana Male, CH K. V. L. S. N., P. Dharani Prasad, A. Santhi Sri, Snehitha Kasu, Mary Asha Prathi und Anusha Nakka. „Assessment of Medication Adherence for Controlling Diabetes in Andhra Pradesh“. In Current Trends in Drug Discovery, Development and Delivery (CTD4-2022), 763–69. Royal Society of Chemistry, 2023. http://dx.doi.org/10.1039/9781837671090-00763.
Der volle Inhalt der QuelleCoumbe, Ben G. T., Elena Nikiphorou und Tuulikki Sokka-Isler. „Combination therapy in rheumatoid arthritis“. In Oxford Textbook of Rheumatoid Arthritis, 457–62. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831433.003.0037.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Disease progression score"
Youssef, Hossam, Nihas Mateti, Demirer Mutlu, Erik Middlebrooks, Thomas Brott, Nilufer Taner, James Meschia und Michelle Lin. „Framingham Risk Score and White Matter Disease Progression (P11-5.009)“. In 2023 Annual Meeting Abstracts. Lippincott Williams & Wilkins, 2023. http://dx.doi.org/10.1212/wnl.0000000000202478.
Der volle Inhalt der QuelleMourão, Lucas, Maria Carthery Goulart, Isabel de Almeida, Peter Garrard und Sônia Brucki. „VALIDATION OF THE MINI LINGUISTIC STATE EXAMINATION (MLSE) TO BRAZILIAN PORTUGUESE: TASKS INTELLIGIBILITY PILOT STUDY“. In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda109.
Der volle Inhalt der QuelleSocher, Karen, Douglas Nunes, Deborah Lopes, Artur Coutinho, Daniele Faria, Paula Squarzoni, Geraldo Busatto Filho, Carlos Buchpighel, Ricardo Nitrini, und Sonia Brucki. „VISUAL MEDIAL TEMPORAL ATROPHY SCALES IN CLINICIAN PRACTICE“. In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda102.
Der volle Inhalt der QuelleCurtis, JR, CH Brahe, M. Ostergaard, ML Hetland, K. Hambardzumyan, S. Saevarsdottir, X. Wang, EH Sasso und TW Huizinga. „THU0091 High multi-biomarker disease activity score is associated with high risk of radiographic progression in six studies“. In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.5557.
Der volle Inhalt der QuelleNeumann, Michael, Hardik Kothare und Vikram Ramanarayanan. „Combining Multiple Multimodal Speech Features into an Interpretable Index Score for Capturing Disease Progression in Amyotrophic Lateral Sclerosis“. In INTERSPEECH 2023. ISCA: ISCA, 2023. http://dx.doi.org/10.21437/interspeech.2023-2100.
Der volle Inhalt der QuelleZia Ur Rehman, Rana, Lynn Rochester, Alison J. Yarnall und Silvia Del Din. „Predicting the Progression of Parkinson’s Disease MDS-UPDRS-III Motor Severity Score from Gait Data using Deep Learning“. In 2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2021. http://dx.doi.org/10.1109/embc46164.2021.9630769.
Der volle Inhalt der QuellePechlivanis, S., N. Lehmann, R. Erbel, KH Jöckel, M. Nöthen und S. Moebus. „Role of Polygenic Risk Score for Coronary Artery Disease and its Traditional Risk Factors with Progression of Coronary Artery Calcification“. In Gemeinsam forschen – gemeinsam handeln. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1605856.
Der volle Inhalt der QuelleCurtis, Jeffrey R., Michael E. Weinblatt, Nancy Shadick, Cecilie Heegaard Brahe, Mikkel Ǿstergaard, Merete L. Hetland, Saedis Saevarsdottir et al. „THU0065 VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS“. In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.6382.
Der volle Inhalt der QuelleJorge, Frederico Mennucci de Haidar, Angela Genge, Ammar Al Chalabi, Orla Hardiman, Alice Shen, Jennifer Shoskes und David Weinstein. „MERIDIAN: A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with amyotrophic lateral sclerosis“. In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.744.
Der volle Inhalt der QuelleQuartuccio, L., S. Zandonella Callegher, S. Gandolfo, C. Fabro und S. De Vita. „FRI0263 Systemic disease activity progression in a large cohort of primary sjÖgren's syndrome: a long-term follow-up data based on the essdai score“. In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3897.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Disease progression score"
Albers, Timothy. Development of an Objective Motor Score for Monitoring the Progression and Severity of Parkinson's Disease. Portland State University Library, Januar 2000. http://dx.doi.org/10.15760/etd.104.
Der volle Inhalt der Quelle